Search research articles
Contact Us
Filters
Showing results (31-40 of 34) with videos related to
Page
of 4
Sort By:
You have reached the last page of results.
This site can display upto 34 results.
Annual Review of Pharmacology and Toxicology
|
October 15, 2017
Application of Microphysiological Systems to Enhance Safety Assessment in Drug Discovery
Lorna Ewart, Eva-Maria Dehne, Kristin Fabre, et al.
Scientific Reports
|
July 5, 2019
On the potential of in vitro organ-chip models to define temporal pharmacokinetic-pharmacodynamic relationships
Christopher W McAleer, Amy Pointon, Christopher J Long, et al.
Computational Toxicology (Amsterdam, Netherlands)
|
June 20, 2022
<i>In silico</i> approaches in organ toxicity hazard assessment: Current status and future needs for predicting heart, kidney and lung toxicities
Arianna Bassan, Vinicius M Alves, Alexander Amberg, et al.
Clinical Pharmacology and Therapeutics
|
September 1, 2020
Time for a Fully Integrated Nonclinical-Clinical Risk Assessment to Streamline QT Prolongation Liability Determinations: A Pharma Industry Perspective
Hugo M Vargas, Michael G Rolf, Todd A Wisialowski, et al.
Page
of 4
Search research articles
Search
Showing results (31-40 of 34) with videos related to
Sort By:
Page
of 4
You have reached the last page of results.
This site can display upto 34 results.
Annual Review of Pharmacology and Toxicology
|
October 15, 2017
Application of Microphysiological Systems to Enhance Safety Assessment in Drug Discovery
Lorna Ewart, Eva-Maria Dehne, Kristin Fabre, et al.
Scientific Reports
|
July 5, 2019
On the potential of in vitro organ-chip models to define temporal pharmacokinetic-pharmacodynamic relationships
Christopher W McAleer, Amy Pointon, Christopher J Long, et al.
Computational Toxicology (Amsterdam, Netherlands)
|
June 20, 2022
<i>In silico</i> approaches in organ toxicity hazard assessment: Current status and future needs for predicting heart, kidney and lung toxicities
Arianna Bassan, Vinicius M Alves, Alexander Amberg, et al.
Clinical Pharmacology and Therapeutics
|
September 1, 2020
Time for a Fully Integrated Nonclinical-Clinical Risk Assessment to Streamline QT Prolongation Liability Determinations: A Pharma Industry Perspective
Hugo M Vargas, Michael G Rolf, Todd A Wisialowski, et al.
Page
of 4